Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
PHASE1
This is a phase 1/2, multicenter, open-label umbrella platform study that w...
Status
Recruiting
Location
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
PHASE2
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroes...